Welcome to our dedicated page for Ensysce Biosciences SEC filings (Ticker: ENSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ensysce Biosciences, Inc. filings document the formal disclosures of a clinical-stage pharmaceutical issuer developing abuse-resistant and overdose-protection opioid technologies. Recent 8-K reports cover financial results, material financing agreements, registered direct and private-placement securities transactions, and amendments or corrections tied to Series B preferred stock, common-stock issuance and warrants.
The company’s regulatory record also includes Nasdaq listing-compliance notices, annual-meeting voting results, incentive-plan amendments, auditor ratification, director elections, board resignations, committee roles and retention-related compensation arrangements. These filings describe Ensysce’s capital structure, governance, public-company compliance obligations and risk-related corporate events while its TAAP™ and MPAR® platforms remain the core operating focus.
Ensysce Biosciences is a clinical-stage biotech focused on TAAP and MPAR technologies; PF614 is in Phase 3 and PF614-MPAR is in Phase 1b. The company reported $2.21 million in cash at June 30, 2025 (from $3.50M), total assets of $5.57 million and total liabilities of $2.51 million. For the six months ended June 30, 2025 the net loss was $3.68 million versus $5.08M a year earlier; federal grant revenue was $2.69 million year-to-date and remaining NIH MPAR grant funding was disclosed as $9.4 million as of June 30, 2025. Management discloses substantial doubt about the company’s ability to continue as a going concern and states current cash is sufficient into the third quarter of 2025. Recent financing actions generated gross proceeds of approximately $2.2M from an April 2025 warrant inducement and approximately $1.1M from a March 2025 registered direct offering, with an additional $1.1M raised from warrant exercises after June 30, 2025. The company carries ~3.42M warrants outstanding and has open purchase commitments of about $8.3M.
Ensysce Biosciences reported that it furnished a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The press release is included as Exhibit 99.1 and the filing also references the company's Inline XBRL cover page. The disclosure clarifies that the press release and related information are furnished, not "filed," and therefore are not incorporated by reference into other securities filings. The report contains a standard forward-looking statements caution describing assumptions, risks, and uncertainties that could cause actual results to differ from expectations. The filing confirms the company's common stock trades under the symbol ENSC on the Nasdaq exchange.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reported beneficial ownership of 74,711 shares of Ensysce Biosciences common stock, representing 3.15% of the company's outstanding shares based on 2,370,698 shares reported in the companys quarterly report. The position is held through Adage entities for which Adage acts as investment manager, and the filing shows shared voting and shared dispositive power over the reported shares rather than sole control.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Because the disclosed stake is below 5%, the filing classifies the ownership as a non-control disclosure under Schedule 13G/A.